#25 / R.T. 7/18

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andrew S. Greenberg	Examiner: Schmidt, M.
Application No: 09/960,647	Group Art Unit: 1635
Filed: October 17, 2000	Confirmation No.: 3460
For: *Methods for Treating and Preventing Insulin Resistance and Related Disorders*	Attorney Ref. No: TUV-005.01

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate of First Class Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22131-1450, on the date set forth below.

July 8, 2003
Date of Signature and Mail Deposit

By: _____
John Barretto

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97 (c)

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to the Applicant and/or his attorney(s) or agent(s) to be in compliance with the requirements of 37 CFR § 1.56 and 1.97. Complete copies of the references are also being submitted herewith.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Form 1449.

This submission does not represent that a search has been made or that no better art exists, nor does it constitute an admission that the cited documents are material or constitute "prior art." If the Examiner applies the listed documents as prior art against any claim in the

application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the referenced documents be applied against the claims of the present application.

Although we believe that we have provided for the fee due in connection with this submission, the Commissioner is authorized to credit any overpayment or charge any deficiencies to/from our ***Deposit Account No. 06-1448, reference TUV-005.01.***

Should there be any questions after reviewing this paper, the Examiner is invited to contact the undersigned at (617) 832-1000.

Respectfully Submitted,

July 8, 2003

Customer No. 25181
Patent Group
Foley Hoag LLP
155 Seaport Boulevard
Boston, MA 02210

Isabelle M. Clauss, Ph.D.
Reg. No. 47,326
Attorney for Applicant

#25

Sheet 1 of 1

ATTY DOCKET NO.	APPLICATION NO
TUV-005.01	09/690,647
APPLICANT	
Greenberg, A.S.	
FILING DATE	GROUP
October 17, 2000	1635

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EG	5,534,426	7/9/96	Karin et al.			
	EH	5,593,884	1/14/97	Karin et al.			
	EI	5,804,399	9/8/98	Karin et al.			
	EJ	5,837,244	11/17/98	Karin et al.			
	EK	5,994,513	11/30/99	Karin et al.			
	EL	6,001,584	12/14/99	Karin et al.			
	EM	6,193,965	2/27/01	Karin et al.			
	EN	6,342,595	1/29/02	Karin et al.			
	EO	6,514,745	2/4/03	Karin et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	EP	Aguirre et al. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem. 2000 Mar 24;275(12):9047-54
	EQ	del Aguila et al. TNF-alpha impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells. Am J Physiol. 1999 May;276(5 Pt 1):E849-55
	ER	Hotamisligil et al. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes. 1999;107(2):119-25. Review
	ES	Le Marchand-Brustel, Y. Molecular mechanisms of insulin action in normal and insulin-resistant states. Exp Clin Endocrinol Diabetes. 1999;107(2):126-32. Review
	ET	Liu et al. Tumor necrosis factor-alpha acutely inhibits insulin signaling in human adipocytes: implication of the p80 tumor necrosis factor receptor. Diabetes. 1998 Apr;47(4):515-22
	EU	Shin et al. An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim Biophys Acta. 2002 May 8;1589(3):311-6
	EV	Spiegelman et al. Regulation of adipocyte gene expression in differentiation and syndromes of obesity/diabetes. J Biol Chem. 1993 Apr 5;268(10):6823-6. Review
	EW	Valverde et al. Tumor necrosis factor-alpha causes insulin receptor substrate-2-mediated insulin resistance and inhibits insulin-induced adipogenesis in fetal brown adipocytes. Endocrinology. 1998 Mar;139(3):1229-38

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.